CapsoVision, Inc — Director's Dealing 2025

Aug 23, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CapsoVision, Inc (CV)
CIK: 0001378325
Period of Report: 2025-08-18

Reporting Person: Petersen Rebecca Ann (Director of Clinical Affairs)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-08-18	Common Stock	M	24834	$0.3663	Acquired	24834	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-08-18	Stock Option (right to buy)	$0.3663	M	7507	Disposed	2031-10-31	Common Stock (7507)	Direct
2025-08-18	Stock Option (right to buy)	$0.3663	M	17327	Disposed	2032-03-22	Common Stock (17327)	Direct

Footnotes

F1: These options were previously reported at exercise price of $0.11 per share. The exercise price reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering.

F2: The option was granted on October 28, 2021 and is fully vested and exercisable as of the transaction date.

F3: There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering.

F4: The option was granted on March 23, 2022 and is partially vested and exercisable as of the transaction date.